We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+26.76%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.78B
AUM Growth
+$199M
Cap. Flow
-$18.8M
Cap. Flow %
-1.06%
Top 10 Hldgs %
47.19%
Holding
82
New
6
Increased
3
Reduced
8
Closed
9

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$38.6M
2
VERU icon
Veru
VERU
+$36.1M
3
EXEL icon
Exelixis
EXEL
+$24.2M
4
VTYX
Ventyx Biosciences
VTYX
+$18.8M
5
GOSS icon
Gossamer Bio
GOSS
+$13.8M

Top Sells

Rank Stock Value
1
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$42.9M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$37.1M
3
BPMC
Blueprint Medicines
BPMC
+$14.9M
4
BMEA icon
Biomea Fusion
BMEA
+$14.2M
5
NUVB icon
Nuvation Bio
NUVB
+$14.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.33%
2 Financials 0.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELEV
76
DELISTED
Elevation Oncology
ELEV
– –
-872,780
Closed -$1.22M
EPIX
77
DELISTED
ESSA Pharma
EPIX
– –
-724,500
Closed -$2.28M
GHRS icon
78
GH Research
GHRS
$1.93B
– –
-1,013,399
Closed -$10.1M
NUVB icon
79
Nuvation Bio
NUVB
$2.2B
– –
-4,341,009
Closed -$14.1M
SLDB icon
80
Solid Biosciences
SLDB
$794M
– –
-355,735
Closed -$3.29M
XBI icon
81
State Street SPDR S&P Biotech ETF
XBI
$9.95B
– –
-500,000
Closed -$37.1M
TPTX
82
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
– –
-570,745
Closed -$42.9M
1 2 3
4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q3 2022 Portfolio in Review

As of Q3 2022, Boxer Capital held 82 positions worth $1.78B, up 13% from $1.58B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Boxer Capital's Q3 2022 filing shows 6 new, 3 increased, 8 reduced and 9 closed positions. Its largest new stake was Veru: 250,000 shares worth $28.8M. The largest sale was Turning Point Therapeutics, Inc. Common Stock, an estimated $42.9M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier, followed by Financials.

  • Boxer Capital's largest Q3 2022 buy was Veru: 250,000 shares worth $28.8M.
  • Boxer Capital added most to SpringWorks Therapeutics in Q3 2022, an estimated $38.6M increase.
  • Boxer Capital's biggest Q3 2022 reduction was Blueprint Medicines, cutting an estimated $14.9M.
  • Boxer Capital fully exited Turning Point Therapeutics, Inc. Common Stock in Q3 2022, selling an estimated $42.9M.
  • Boxer Capital's ten largest holdings make up 47% of its $1.78B portfolio in Q3 2022.
  • Boxer Capital opened 6 new positions and closed 9 in Q3 2022.
  • Boxer Capital's portfolio value rose 13% quarter-over-quarter to $1.78B.

Based on Boxer Capital's 13F filing for Q3 2022, filed 14 Nov 2022.